H.C. Wainwright lowered the firm’s price target on Arvinas (ARVN) to $81 from $87 and keeps a Buy rating on the shares. Given the company’s pipeline development and progress, the firm reevaluated its spending assumption going forward.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas Holding Company Receives ‘Buy’ Rating: Promising Clinical Advances and Strategic Pipeline Developments
- Arvinas Reports 2024 Financial Results and Pipeline Progress
- Positive Outlook for Arvinas’ Vepdeg and Strategic Expansion Justifies Buy Rating
- Arvinas reports Q4 EPS (63c), consensus (96c)
- Arvinas sees cash runway into 2027